BridgeBio Pharma Inc. filed a Form S-1 for a proposed IPO of up to $225 million of its common stock.
The Palo Alto, Calif.-based biopharmaceutical company, which is focused on developing treatments for genetic diseases, seeks to list its shares on the Nasdaq Global Market under the ticker BBIO.
BridgeBio plans to use the net proceeds to fund its ongoing product development, preclinical and clinical studies, as well as discovery research and development. The funds will also be used for working capital and general corporate purposes.
The company may also use the proceeds to make investments or to in-license, acquire or invest in new businesses, technology or assets.
BridgeBio's pipeline of over 15 development programs includes potential drugs in early discovery to late-stage development focused on Mendelian diseases, which are diseases that arise from defects in a single gene and cancers with clear genetic drivers.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Jefferies LLC, SVB Leerink LLC, KKR Capital Markets LLC, Piper Jaffray & Co., Mizuho Securities USA LLC, BMO Capital Markets Corp. and Raymond James & Associates Inc. will be the underwriters for the IPO.